Sumary of Kazia (ASX:KZA) share price slides despite positive update:
- In its announcement, Kazia shared some key points of its ongoing phase II study of paxalisib in glioblastoma – a common and very aggressive type of brain cancer..
- Kazia noted that the data is subject to a poster presentation at the Association of Cancer Research (AACR) annual meeting..
- More broadly, the phase II study is drawing to a conclusion, and we expect to be able to share final data in the second half of this year..
- Kazia share price summary Over the past 12 months, the Kazia share price has soared more than 300%, reflecting positive investor sentiment….